Post by Discovery Life Sciences

Patient survival in oncology is measured in months. Trial enrollment windows are measured in weeks. Yet across Europe, sponsors and CROs running oncology trials still face the same blocker: IVDR-compliant prospective testing typically carries a performance study burden that can stretch program startup by months, or routes through reference labs quoting 20-to-30-day turnarounds. Neither timeline fits the patients these trials are meant to reach. Today we're launching Luminos® Comprehensive to close that gap. A 164-gene pan-tumor CGP panel. Validated as an IVDR-compliant LDT. Deployed in-house at Discovery Life Sciences' Kassel, Germany facility under Health Institution status per IVDR Article 5(5). Results in 7 to 10 business days. Built for: - Enrollment screening across pan-tumor protocols  - Biomarker stratification covering actionable oncogenes, emerging TKI targets (KEAP1, ATM), and DDR pathways  - Prospective EU clinical use without the performance study burden or third-party reference lab routing    Scott Reid, VP and Global Head of Companion Diagnostics, on the gap Luminos was built to close: "We hear the same conversation from sponsors and CROs constantly. They need IVDR-compliant prospective testing, but the performance study burden can add months to study startup. That doesn't work when enrollment windows are measured in weeks and patient survival is measured in months." Luminos® Comprehensive is commercially available today, six days ahead of the May 26 IVDR Class C enforcement deadline. We'll be at ASCO 2026 in Chicago, May 29 to June 2. Technical specifications, full gene list, and performance summary: https://lnkd.in/gwD8uN29 Press release in the comments. #Oncology #IVDR #ClinicalTrials #GenomicProfiling #ASCO26

Video Content